Fred Alger Management Inc. trimmed its stake in shares of Spark Therapeutics Inc (NASDAQ:ONCE) by 36.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,000 shares of the biotechnology company’s stock after selling 12,277 shares during the quarter. Fred Alger Management Inc.’s holdings in Spark Therapeutics were worth $1,080,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in ONCE. Gilder Gagnon Howe & Co. LLC bought a new stake in shares of Spark Therapeutics during the 4th quarter worth about $28,188,000. Orbimed Advisors LLC acquired a new position in shares of Spark Therapeutics in the 3rd quarter worth approximately $38,340,000. Rockefeller Financial Services Inc. grew its stake in shares of Spark Therapeutics by 27,905.0% in the 4th quarter. Rockefeller Financial Services Inc. now owns 353,983 shares of the biotechnology company’s stock worth $18,202,000 after purchasing an additional 352,719 shares during the last quarter. Jennison Associates LLC acquired a new position in shares of Spark Therapeutics in the 3rd quarter worth approximately $27,239,000. Finally, JPMorgan Chase & Co. grew its stake in shares of Spark Therapeutics by 15.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock worth $164,986,000 after purchasing an additional 241,016 shares during the last quarter.

How to Become a New Pot Stock Millionaire

Several equities analysts have recently issued reports on ONCE shares. BMO Capital Markets reaffirmed a “buy” rating and issued a $101.00 price objective on shares of Spark Therapeutics in a research note on Wednesday, November 15th. Credit Suisse Group started coverage on shares of Spark Therapeutics in a research note on Wednesday, January 17th. They issued an “outperform” rating and a $61.00 price objective on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $105.00 price objective on shares of Spark Therapeutics in a research note on Wednesday, January 24th. Barclays reaffirmed a “buy” rating and issued a $54.00 price objective on shares of Spark Therapeutics in a research note on Wednesday, December 13th. Finally, Goldman Sachs Group cut shares of Spark Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $106.00 to $58.00 in a research note on Thursday, December 14th. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and sixteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $70.58.

Spark Therapeutics Inc (ONCE) opened at $63.63 on Wednesday. Spark Therapeutics Inc has a 1 year low of $41.06 and a 1 year high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last released its earnings results on Tuesday, February 20th. The biotechnology company reported ($1.73) earnings per share for the quarter, hitting the consensus estimate of ($1.73). The business had revenue of $7.41 million for the quarter, compared to the consensus estimate of $9.53 million. Spark Therapeutics had a negative net margin of 2,100.80% and a negative return on equity of 59.38%. sell-side analysts predict that Spark Therapeutics Inc will post -3.68 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Spark Therapeutics Inc (ONCE) Holdings Lowered by Fred Alger Management Inc.” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2018/03/14/spark-therapeutics-inc-once-holdings-lowered-by-fred-alger-management-inc.html.

Spark Therapeutics Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics Inc (NASDAQ:ONCE).

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.